On Monday, April 24, 2017, Fresenius Kabi and Merck KGaA announced that Fresenius will be acquiring Merck KGaA’s biosimilars business. According to Merck KGaA’s press release, Merck KGaA’s biosimilar portfolio focuses on oncology and inflammatory disorders. Both companies report that the transaction is expected to close in the second half of 2017, subject to regulatory approvals and other customary closing conditions.

Further information about Merck KGaA’s biosimilar business, and the financial terms of the deal are provided in Fresenius Kabi’s and Merck KGaA’s respective press releases (which can be found here, and here).